- Q1 2023 Minerva Neurosciences Inc Earnings Call TranscriptMay 15, 2023$6.44 (-11.42%)Earnings
- Q4 2022 Minerva Neurosciences Inc Earnings Call TranscriptMar 08, 2023$1.87 (-7.65%)Earnings
- Q3 2022 Minerva Neurosciences Inc Earnings Call TranscriptNov 09, 2022$3.26 (+8.85%)Earnings
- Minerva Neurosciences Inc Roluperidone Update Call TranscriptApr 13, 2022
- Q3 2021 Minerva Neurosciences Inc Earnings Call TranscriptNov 08, 2021$11.28 (+4.44%)Earnings
- Q2 2021 Minerva Neurosciences Inc Earnings Call TranscriptAug 02, 2021$14.72Earnings
- Minerva Neurosciences Inc at JMP Securities Life Sciences Virtual Conference TranscriptJun 16, 2021
- Minerva Neurosciences Inc Annual Shareholders Meeting TranscriptJun 11, 2021
- Q1 2021 Minerva Neurosciences Inc Earnings Call TranscriptMay 12, 2021$20.64 (+15.70%)Earnings
- Q4 2020 Minerva Neurosciences Inc Earnings Call TranscriptMar 08, 2021$25.52 (+11.54%)Earnings
- Q3 2020 Minerva Neurosciences Inc Earnings Call TranscriptNov 02, 2020$24.8 (-3.43%)Earnings
- Minerva Neurosciences Inc at Citi BioPharma Conference (Virtual) TranscriptSep 09, 2020
- Q2 2020 Minerva Neurosciences Inc Earnings Call TranscriptAug 03, 2020$29.52 (+5.88%)Earnings
- Minerva Neurosciences Inc Annual Shareholders Meeting TranscriptJun 19, 2020
- Minerva Neurosciences, Inc. - Special Call TranscriptJun 05, 2020
- Q1 2020 Minerva Neurosciences Inc Earnings Call TranscriptMay 04, 2020$78 (+3.83%)Earnings
- Minerva Neurosciences, Inc. - Special Call TranscriptMar 31, 2020
- Q4 2019 Minerva Neurosciences Inc Earnings Call TranscriptMar 09, 2020$57.6 (-14.59%)Earnings
- Minerva Neurosciences, Inc. - Special Call TranscriptMar 06, 2020
- Minerva Neurosciences, Inc. - Special Call TranscriptDec 18, 2019
- Q3 2019 Minerva Neurosciences Inc Earnings Call TranscriptNov 04, 2019$37.2 (+0.65%)Earnings
- Minerva Neurosciences, Inc. - Special Call TranscriptOct 01, 2019
- Q2 2019 Minerva Neurosciences Inc Earnings Call TranscriptAug 05, 2019$55.76 (+8.06%)Earnings
- Minerva Neurosciences Inc To Discuss The Results Of Its Successful Phase 2b Clinical Trial Of Seltorexant MIN-202 In Insomnia TranscriptJun 24, 2019
- Q1 2019 Minerva Neurosciences Inc Earnings Call TranscriptMay 06, 2019$57.52 (-5.15%)Earnings
- Minerva Neurosciences, Inc. - Special Call TranscriptMar 21, 2019
- Q4 2018 Minerva Neurosciences Inc Earnings Call TranscriptMar 12, 2019$64.88 (-0.37%)Earnings
Minerva Neurosciences Inc To Discuss The Results Of Its Successful Phase 2b Clinical Trial Of Seltorexant MIN-202 In Insomnia Transcript
Good morning, everyone. Welcome to the June 24, 2019, Minerva Neurosciences conference call announcing the top line results from the company's Phase IIb trial in insomnia with seltorexant, a specific orexin-2 receptor antagonist.
A press release was issued this morning announcing data from this trial and providing conference call dial-in information.
Dr. Rémy Luthringer, Executive Chairman and Chief Executive Officer of Minerva, will be joined on the call today by 2 key opinion leaders in insomnia. Dr. Thomas Roth is Director of the Sleep Disorders and Research Center at the Henry Ford Hospital in Detroit, Michigan. Dr. David Kupfer is distinguished professor emeritus, department of psychiatry, University of Pittsburgh School of Medicine and a Board member of Minerva Neurosciences.
Dr. Luthringer will begin with brief introductory remarks. He will be followed by Dr. Roth and then by Dr. Kupfer. Dr. Luthringer will then provide a recap and open the floor to questions.
With that, I
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)